Ospedale Meyer-Reumatologia, Firenze, Italy.
Pediatr Rheumatol Online J. 2009 Oct 23;7:18. doi: 10.1186/1546-0096-7-18.
Undiagnosed patients with the attenuated form of mucopolysaccharidosis (MPS) type I often have joint symptoms in childhood that prompt referral to a rheumatologist. A survey conducted by Genzyme Corporation of 60 European and Canadian rheumatologists and pediatric rheumatologists demonstrated that < 20% recognized signs and symptoms of MPS I or could identify appropriate diagnosis tests. These results prompted formation of an international working group of rheumatologists, pediatric rheumatologists, and experts on MPS I to formulate a rheumatology-based diagnostic algorithm. The resulting algorithm applies to all MPS disorders with musculoskeletal manifestations.Bone and joint manifestations are prominent among most patients with MPS disorders. These life-threatening lysosomal storage diseases are caused by deficient activity of specific enzymes involved in the degradation of glycosaminoglycans. Patients with attenuated MPS disease often experience diagnostic delays. Enzyme replacement therapy is now commercially available for MPS I (laronidase), MPS II (idursulfase), and MPS VI (galsulfase).
Evolving joint pain and joint contractures in the absence of inflammation should always raise the suspicion of an MPS disorder. All such patients should undergo urinary glycosaminoglycan (uGAG) analysis (not spot tests for screening) in a reputable laboratory. Elevated uGAG levels and/or an abnormal uGAG pattern confirms an MPS disorder and specific enzyme testing will determine the MPS type. If uGAG analysis is unavailable and the patient exhibits any other common sign or symptom of an MPS disorder, such as corneal clouding, history of hernia surgery, frequent respiratory and/or ear, nose and throat infections; carpal tunnel syndrome, or heart murmur, proceed directly to enzymatic testing. Refer patients with confirmed MPS to a geneticist or metabolic specialist for further evaluation and treatment.
We propose that rheumatologists, pediatric rheumatologists, and orthopedists consider our diagnostic algorithm when evaluating patients with joint pain and joint contractures.
Children and young adults can suffer for years and sometimes even decades with unrecognized MPS. Rheumatologists may facilitate early diagnosis of MPS based on the presenting signs and symptoms, followed by appropriate testing. Early diagnosis helps ensure prompt and appropriate treatment for these progressive and debilitating diseases.
未确诊的黏多糖贮积症(MPS)I 型衰减患者在儿童时期常有关节症状,这会促使他们转至风湿病医生处就诊。健赞公司对 60 名欧洲和加拿大的风湿病医生和儿科风湿病医生进行的一项调查显示,<20%的医生能够识别 MPSI 的体征和症状,或能够识别适当的诊断检测。这些结果促使一组由风湿病医生、儿科风湿病医生和 MPSI 专家组成的国际工作组制定了一个基于风湿病的诊断算法。由此产生的算法适用于所有有肌肉骨骼表现的黏多糖贮积症。骨骼和关节表现是大多数黏多糖贮积症患者的突出表现。这些危及生命的溶酶体贮积病是由参与糖胺聚糖降解的特定酶活性缺乏引起的。衰减型 MPS 疾病患者经常出现诊断延迟。目前已可获得用于 MPSI(拉罗酶)、MPSII(依地硫酸酶)和 MPSVI(加硫酶)的酶替代疗法。
在没有炎症的情况下,逐渐出现的关节疼痛和关节挛缩应始终提示黏多糖贮积症。所有此类患者均应在信誉良好的实验室中进行尿糖胺聚糖(uGAG)分析(而不是用于筛查的点测试)。uGAG 水平升高和/或 uGAG 模式异常可确认黏多糖贮积症,特定的酶检测将确定 MPS 类型。如果无法进行 uGAG 分析,且患者存在黏多糖贮积症的任何其他常见体征或症状,如角膜混浊、疝修补术史、频繁的呼吸道和/或耳、鼻和喉感染、腕管综合征或心脏杂音,则直接进行酶检测。将确诊的 MPS 患者转介给遗传学家或代谢专家,以进行进一步评估和治疗。
我们建议风湿病医生、儿科风湿病医生和矫形外科医生在评估有关节疼痛和关节挛缩的患者时考虑我们的诊断算法。
儿童和青年可能会在未被识别的 MPS 中痛苦多年,有时甚至数十年。风湿病医生可以根据现有体征和症状促进 MPS 的早期诊断,随后进行适当的检测。早期诊断有助于确保对这些进行性和使人衰弱的疾病进行及时和适当的治疗。